Literature DB >> 12094862

Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease.

Cornelia M Gelbmann1, Gerhard Rogler, Volker Gross, Michael Gierend, Nicole Bregenzer, Tilo Andus, Jürgen Schölmerich.   

Abstract

OBJECTIVES: Some patients with Crohn's disease (CD) do not respond to corticosteroid therapy. Furthermore, corticosteroids frequently cause side effects. Thus, predictive parameters for treatment refractoriness would be helpful for treatment decisions.
METHODS: A total of 300 patients with active CD (i.e., with a Crohn's Disease Activity Index [CDAI] >200) entered the study. Treatment started with 60-100 mg/day prednisolone equivalent, which was then tapered to 10-15 mg/day within 6 wk and maintained at that dose for another 4 wk. After 10 wk of treatment, response to steroids was defined by a CDAI <150, steroid resistance by a CDAI always > or =150 and steroid dependency by a relapse after dose reduction. Of 239 eligible patients, 196 were responders, 26 were steroid resistant, and 17 were steroid dependent.
RESULTS: Prior bowel resections, a high initial CDAI, and perianal disease were associated with steroid resistance. Of the steroid resistant patients 53.9% were bowel-resected compared to 20.4% of the responders (relative risk = 3.63; 95% CI = 1.79-7.36). Perianal disease was observed in 42.3% of steroid resistant patients versus 21.9% of responders (relative risk = 2.28; 95% CI = 1.12-4.66) and initial CDAI was 347+/-91 in resistant patients versus 301+/-81 in responders (p < 0.05). Parameters for steroid dependent patients were not significantly different from those of responders.
CONCLUSIONS: In this study (thus far the largest study for the evaluation of predictive factors for treatment refractoriness to corticosteroids in CD), only prior bowel resection, perianal disease, and a high initial CDAI were found to be predictive of resistance to steroid treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12094862     DOI: 10.1111/j.1572-0241.2002.05685.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  9 in total

Review 1.  Multidisciplinary and evidence-based management of fistulizing perianal Crohn's disease.

Authors:  Ricardo Sordo-Mejia; Wolfgang B Gaertner
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

2.  Long term follow up of through-the-scope balloon dilation as compared to strictureplasty and bowel resection of intestinal strictures in crohn's disease.

Authors:  Ekaterina Krauss; Abbas Agaimy; Angelina Gottfried; Juergen Maiss; Thomas Weidinger; Heinz Albrecht; Arndt Hartmann; Werner Hohenberger; Markus F Neurath; Hermann Kessler; Jonas Mudter
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

3.  Efficacy and complications of surgery for Crohn's disease.

Authors:  Robert T Lewis; David J Maron
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-09

Review 4.  Use of exclusive enteral nutrition in adults with Crohn's disease: a review.

Authors:  Catherine L Wall; Andrew S Day; Richard B Gearry
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 5.  Surgical treatment of anorectal crohn disease.

Authors:  Robert T Lewis; Joshua I S Bleier
Journal:  Clin Colon Rectal Surg       Date:  2013-06

6.  Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn's Disease: A Hospital-Based Cohort Study.

Authors:  Sang Hyoung Park; Sung Wook Hwang; Min Seob Kwak; Wan Soo Kim; Jeong-Mi Lee; Ho-Su Lee; Dong-Hoon Yang; Kyung-Jo Kim; Byong Duk Ye; Jeong-Sik Byeon; Seung-Jae Myung; Yong Sik Yoon; Chang Sik Yu; Jin-Ho Kim; Suk-Kyun Yang
Journal:  Dig Dis Sci       Date:  2016-03-12       Impact factor: 3.199

7.  Therapy for unhealed gastrocutaneous fistulas in rats as a model for analogous healing of persistent skin wounds and persistent gastric ulcers: stable gastric pentadecapeptide BPC 157, atropine, ranitidine, and omeprazole.

Authors:  Sandra Skorjanec; Zdravko Dolovski; Ivan Kocman; Luka Brcic; Alenka Blagaic Boban; Lovorka Batelja; Marjana Coric; Marko Sever; Robert Klicek; Lidija Berkopic; Bozo Radic; Domagoj Drmic; Danijela Kolenc; Spomenko Ilic; Vedran Cesarec; Ante Tonkic; Ivan Zoricic; Stjepan Mise; Mario Staresinic; Mihovil Ivica; Martina Lovric Bencic; Tomislav Anic; Sven Seiwerth; Predrag Sikiric
Journal:  Dig Dis Sci       Date:  2008-07-23       Impact factor: 3.199

8.  Medical and surgical treatment of haemorrhoids and anal fissure in Crohn's disease: a critical appraisal.

Authors:  Stefano D'Ugo; Luana Franceschilli; Federica Cadeddu; Laura Leccesi; Giovanna Del Vecchio Blanco; Emma Calabrese; Giovanni Milito; Nicola Di Lorenzo; Achille L Gaspari; Pierpaolo Sileri
Journal:  BMC Gastroenterol       Date:  2013-03-11       Impact factor: 3.067

9.  Association of Perianal Fistulas with Clinical Features and Prognosis of Crohn's Disease in Korea: Results from the CONNECT Study.

Authors:  Jaeyoung Chun; Jong Pil Im; Ji Won Kim; Kook Lae Lee; Chang Hwan Choi; Hyunsoo Kim; Jae Hee Cheon; Byong Duk Ye; Young-Ho Kim; You Sun Kim; Yoon Tae Jeen; Dong Soo Han; Won Ho Kim; Joo Sung Kim
Journal:  Gut Liver       Date:  2018-09-15       Impact factor: 4.519

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.